JP2025060686A5 - - Google Patents

Info

Publication number
JP2025060686A5
JP2025060686A5 JP2024218275A JP2024218275A JP2025060686A5 JP 2025060686 A5 JP2025060686 A5 JP 2025060686A5 JP 2024218275 A JP2024218275 A JP 2024218275A JP 2024218275 A JP2024218275 A JP 2024218275A JP 2025060686 A5 JP2025060686 A5 JP 2025060686A5
Authority
JP
Japan
Prior art keywords
composition
atrasentan
human subject
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024218275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025060686A (ja
JP7821870B2 (ja
Filing date
Publication date
Priority claimed from JP2022537007A external-priority patent/JP7624995B2/ja
Application filed filed Critical
Publication of JP2025060686A publication Critical patent/JP2025060686A/ja
Publication of JP2025060686A5 publication Critical patent/JP2025060686A5/ja
Application granted granted Critical
Publication of JP7821870B2 publication Critical patent/JP7821870B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024218275A 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法 Active JP7821870B2 (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962949115P 2019-12-17 2019-12-17
US62/949,115 2019-12-17
US202063005003P 2020-04-03 2020-04-03
US63/005,003 2020-04-03
US202063072699P 2020-08-31 2020-08-31
US63/072,699 2020-08-31
US202063084739P 2020-09-29 2020-09-29
US63/084,739 2020-09-29
US202063125205P 2020-12-14 2020-12-14
US63/125,205 2020-12-14
JP2022537007A JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法
PCT/US2020/065311 WO2021126977A1 (en) 2019-12-17 2020-12-16 Methods of treating iga nephropathy with atrasentan

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022537007A Division JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法

Publications (3)

Publication Number Publication Date
JP2025060686A JP2025060686A (ja) 2025-04-10
JP2025060686A5 true JP2025060686A5 (https=) 2025-10-27
JP7821870B2 JP7821870B2 (ja) 2026-02-27

Family

ID=76478538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537007A Active JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法
JP2024218275A Active JP7821870B2 (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022537007A Active JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法

Country Status (21)

Country Link
US (11) US20210353593A1 (https=)
EP (2) EP4076652B1 (https=)
JP (2) JP7624995B2 (https=)
KR (1) KR20230015874A (https=)
CN (3) CN116327758A (https=)
AU (1) AU2020404984A1 (https=)
BR (1) BR112022012075A2 (https=)
CA (1) CA3161516A1 (https=)
DK (1) DK4076652T3 (https=)
FI (1) FI4076652T3 (https=)
HR (1) HRP20260121T1 (https=)
IL (1) IL293921A (https=)
LT (1) LT4076652T (https=)
MX (1) MX2022007471A (https=)
PH (1) PH12022551456A1 (https=)
PL (1) PL4076652T3 (https=)
PT (1) PT4076652T (https=)
RS (1) RS67746B1 (https=)
SI (1) SI4076652T1 (https=)
TW (1) TWI875895B (https=)
WO (1) WO2021126977A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
WO2023220930A1 (en) * 2022-05-17 2023-11-23 Increvet, Inc. Veterinary pharmaceutical formulations cross-references to related applications
JP2025517355A (ja) * 2022-05-19 2025-06-05 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
WO2024076177A1 (ko) * 2022-10-05 2024-04-11 주식회사 대웅제약 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물
EP4608396A1 (en) * 2022-10-28 2025-09-03 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
JP2025536433A (ja) 2022-11-07 2025-11-05 サンレノ セラピューティクス （シャンハイ） リミテッド ＩｇＡ腎症を治療するためのエンドセリン受容体アンタゴニストとグルココルチコイドとの組み合わせ
WO2025261457A1 (zh) * 2024-06-21 2025-12-26 深圳信立泰药业股份有限公司 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US20020062121A1 (en) 1995-05-16 2002-05-23 Karl Tryggvason Perfusion apparatus and methods for pharmaceutical delivery
ES2259803T3 (es) 1996-02-13 2006-10-16 Abbott Laboratories Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
US20040191774A1 (en) 2001-09-11 2004-09-30 Moskowitz David W Endothelin-1 promoter polymorphism
WO2003080038A1 (en) 2002-03-22 2003-10-02 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for kidney disease
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US20030229906A1 (en) 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
CA2578824A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
US8231907B2 (en) 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
AU2007230580A1 (en) * 2006-03-27 2007-10-04 Genentech, Inc. Methods for treating kidney disorders
WO2007119214A2 (en) 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
NZ578164A (en) 2007-01-16 2011-12-22 Musc Found For Res Dev Compositions and methods for diagnosing, treating, and preventing prostate conditions
AU2008282773B8 (en) 2007-07-31 2013-03-07 Gilead Sciences, Inc. Metabolites and derivatives of ambrisentan
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
EP3708163A1 (en) 2009-03-31 2020-09-16 Ligand Pharmaceuticals, Inc. Use of sparsentan for the treatment of chronic inflammatory diseases
EP2509594A1 (en) 2009-12-09 2012-10-17 INSERM - Institut National de la Santé et de la Recherche Médicale Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
US9365445B2 (en) 2010-07-28 2016-06-14 Nippon Electric Glass Co., Ltd. Method for producing phosphor-encapsulating capillary tube, phosphor-encapsulating capillary tube, wavelength-converting member, and method for producing wavelength-converting member
US20160015701A1 (en) * 2013-03-08 2016-01-21 Abbive Inc. Methods of Treating Acute Kidney Injury
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
CA2916033C (en) * 2013-07-08 2022-08-23 Abbvie Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
JP2017534634A (ja) * 2014-11-07 2017-11-24 アッヴィ・インコーポレイテッド 体液貯留の予測因子を使用してｃｋｄを処置する方法
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170014386A1 (en) 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
MA43260A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
US10736960B2 (en) 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
JP2019530713A (ja) * 2016-10-13 2019-10-24 レトロフィン， インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
MX2021014356A (es) 2016-11-23 2022-11-24 Chemocentryx Inc Metodo para tratar glomeruloesclerosis segmentaria focal.
AU2018347361A1 (en) 2017-10-11 2020-04-30 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
KR20260037123A (ko) 2017-11-30 2026-03-17 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
KR20230015874A (ko) * 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
US20220304979A1 (en) 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
JP2023521169A (ja) 2020-04-10 2023-05-23 チヌーク セラピューティクス，インコーポレイテッド 糖尿病性腎疾患の処置方法
US20220243994A1 (en) 2021-02-04 2022-08-04 Northrop Grumman Systems Corporation Metal woodpile capillary wick

Similar Documents

Publication Publication Date Title
JP2025060686A5 (https=)
EP4512397A2 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
CN105263579B (zh) 左西替利嗪和孟鲁司特在治疗血管炎中的用途
JP2024127897A5 (https=)
TWI406858B (zh) 炎症性腸道疾病治療藥
US20150320721A1 (en) Combinations of sglt 2 inhibitors and antihypertensive drugs
Dominguez Rieg et al. New functions and roles of the Na+-H+-exchanger NHE3
Fenier et al. Enalapril improved renal function and proteinuria in chronic glomerulopathies
WO2015129750A1 (ja) 慢性腎臓病の進行抑制又は改善剤
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
EP3090744A1 (en) Pharmaceutical complex formulation comprising angiotensin ii receptor blocker and hmg-coa reductase inhibitor
US20110130421A1 (en) Methods and Compositions for the Treatment of Chronic Renal Hypertension
JP2024520138A (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
Sahai et al. Pharmacology of the Therapeutic Approaches of Gout
KR20230119303A (ko) 높은 혈중 요산 농도를 갖는 대상체의 만성 신장 질환의 예방 또는 치료를 위한 알로푸리놀, 페북소스타트 또는 이들의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
EP2586442A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
CN100453081C (zh) 用于治疗糖尿病性肾病的吡啶基亚磺酰氨基嘧啶
RU2741426C1 (ru) Никотинамид для лечения дислипидемии
CN101014333A (zh) 包含洛索洛芬的口服组合物
Varda et al. Diabetic Kidney Disease: From Pathophysiology To Treatment Perspectives
TWI907583B (zh) Jak抑制劑在腎臟疾病中的應用
WO2022225044A1 (ja) カリウム吸着薬を有効成分とする慢性腎不全（ｃｋｄ）合併高カリウム血症患者の予後改善剤
Groothoff et al. Long-Term Nedosiran Safety and Efficacy in Primary Hyperoxaluria Type 1 (PH1): Interim Analysis of PHYOX3: TH-PO1128
Ye et al. Nonsteroidal anti-inflammatory drug use and acute kidney injury in nephrectomies: A retrospective propensity score-matched cohort study
JPWO2019232306A5 (https=)